Introduction {#sec1-1}
============

Breast cancer is a molecularly heterogeneous disorder associated with high mortality and morbidity (Seifi-Alan et al., 2013; Iranpour et al., 2016). Among the most important factors contributing in breast cancer are genes involved in maintenance of genomic integrity (Walsh and King, 2007). Partner and localizer of *BRCA2 (PALB2)* encodes a protein which co-localizes with *BRCA2* in nuclear foci, enhances its stability in chromatin and nuclear matrix and facilitates its tumor suppression effect (Xia et al., 2006). In addition, it provides the functional link between BRCA1 and *BRCA2*. It coheres directly to BRCA1, and makes the molecular scaffold for establishment of the BRCA1-*PALB2*-*BRCA2* complex. Its interaction with BRCA1 is mainly facilitated via apolar bonding between their corresponding coiled-coil domains. Noticeably, BRCA1 mutations detected in cancer patients abolish such interactions resulting in insufficiency of homologous recombination (HR) repair. In brief, *PALB2* makes the molecular link between the BRCA proteins and its mutations lead to defective HR repair, genomic instability and carcinogenesis (Sy et al., 2009). As revealed by in vitro studies, many of *BRCA2* functions including G2/M checkpoint, replication fork shields and repair of double strand breaks by HR depend on its interaction with *PALB2* (Hartford et al., 2016). Germ line mutations in *PALB2* have been shown to increase breast cancer risk in different populations (Rahman et al., 2007; Cao et al., 2009; Antoniou et al., 2014). However, breast cancer susceptibility is best explained by a "polygenic" model, in which several loci confer breast cancer risk, with each locus having only a minor influence (Pharoah et al., 2002). Consequently, in addition to high risk mutations, many low-penetrance variants such as single nucleotide polymorphisms (SNPs) in *PALB2* might interactively affect the risk of breast cancer development (Cao et al., 2010). The associations between *PALB2* SNPs and breast cancer risk have been evaluated in different populations (Chen et al., 2008; Cao et al., 2010; Guenard et al., 2010; Jiang et al., 2016). However, the results of these studies are inconclusive and inconsistent in some cases. Such inconsistency might be explained by the moderately small sample size of former studies or the inherent genetic heterogeneity of breast cancer in diverse populations. Therefore, we designed a meta-analysis to resolve these incompatible results and to achieve a conclusive decision regarding the role of *PALB2* variants in genetic susceptibility to breast cancer. The selection of *PALB2* for the meta-analysis was based on the previous reports indicating its co-localization with *BRCA2* and its putative role in the pathogenesis of breast cancer.

Materials and Methods {#sec1-2}
=====================

Literature search {#sec2-1}
-----------------

The studies included in the meta-analysis were chosen by searching the PubMed, Google scholar and Embase databases from their establishment to January 2018 using the following keywords: "*PALB2* gene or Partner and localizer of *BRCA2*" AND "breast cancer or breast carcinoma". We also assessed all references in of the retrieved studies to detect extra research not included in the databases. We just assessed researches written in English. [Figure 1](#F1){ref-type="fig"} shows the flowchart of course of selection of articles for inclusion in the current meta-analysis.

Inclusion criteria {#sec2-2}
------------------

The following criteria was adopted to include studies in the current meta-analysis: (1) a case-control study scheme; (2) a concentration on the association of *PALB2* SNPs with breast cancer risk; (3) satisfactory data to determine the odds ratio (OR), confidence interval (CI) and P value; (4) compliance of genotype distribution of all control groups with Hardy-Weinberg equilibrium (HWE).

Data extraction and quality assessment {#sec2-3}
--------------------------------------

Two researchers (AD and SF) evaluated eligible studies and extracted first author's name, publication year, sample size, country, ethnicity, source of DNA used for genotyping, and frequencies of each genotype in certain study groups. The quality of the studies was evaluated using Newcastle-Ottawa scale (NOS) (Stang, 2010). In the cases of missing data in the obtained studies, the mentioned researchers gathered the missing data through communication (via email) with the corresponding authors.

Statistical analyses {#sec2-4}
--------------------

All analyses were performed in the RevMan (v.5.1) software (<http://www.cochrane.org/revman>). We assessed the association between *PALB2* SNPs and breast cancer using Z test to appraise the significance of the pooled odds ratios (OR). ORs were computed in allelic (wild type (W) versus minor (M)), homozygote (WW versus MM), dominant (WW+WM versus MM) and recessive (WW versus WM+MM) models. The grade of heterogeneity between the studies was evaluated using Q-test and I2 parameter. The values up to 40% were considered acceptable. Based on the calculated P values, OR and 95% CI (for the pooled odds ratio) were computed using random-effect model or fixed-effect model in heterogeneous or homogenous states respectively. Publication bias was evaluated using Begg's and Egger's tests. The level of significance was set at P\<0.05.

Results {#sec1-3}
=======

Results of literature search {#sec2-5}
----------------------------

After initial assessment of titles and abstracts of found manuscripts, 201 manuscripts were reviewed for inclusion ([Figure 1](#F1){ref-type="fig"}). A total of 187 studies were filtered due to unsuitable study design, unsuitable type of study (studies other than original research) or language. Fourteen studies were subjected to detailed evaluation. Finally, we chose six articles for inclusion in the current meta-analysis (Chen et al., 2008; Cao et al., 2010; Guenard et al., 2010; Loizidou et al., 2010; Leyton et al., 2015; Jiang et al., 2016). [Table 1](#T1){ref-type="table"} shows the characteristics of studies included in the meta-analysis and the obtained NOS scores.

![A Systematic Flow Chart Depicting the Sequence of Selection of Articles for This Meta-analysis.](APJCP-19-2897-g001){#F1}

###### 

Characteristics of Studies Included in the Meta-analysis

  Study Name        Year   Country   Source of DNA   Ethnicity         No. of Cases   No. of Controls   Genotype frequency in controls   Genotype frequency in cases   NOS Score   HWE/ Chi-Square                   
  ----------------- ------ --------- --------------- ----------------- -------------- ----------------- -------------------------------- ----------------------------- ----------- ----------------- ----- ----- --- --------------
  rs45532440                                                                                                                                                                                                         
  Loizidou et al.   2010   Cyprus    Blood           Caucasian         1,102          1,159             1,035                            120                           4           972               126   4     7   0.7931/0.07
  Gue´nard et al.   2010   Canada    Blood           French Canadian   96             95                92                               2                             1           88                8     0     8   0.0000/22.74
  rs249954                                                                                                                                                                                                           
  Chen et al.       2008   China     Blood           Asian             1,010          1,033             412                              477                           144         331               524   155   7   0.7521/0.10
  Cao et al.        2009   China     Blood           Asian             660            756               281                              361                           113         256               321   82    7   0.8667/0.03
  Gue´nard et al.   2010   Canada    Blood           French Canadian   96             86                55                               29                            2           56                36    4     8   0.4175/0.66
  Jiang et al.      2016   China     Blood           Asian             351            360               176                              156                           28          131               174   46    7   0.4153/0.66
  rs45551636                                                                                                                                                                                                         
  Loizidou et al.   2009   Cyprus    Blood           Caucasian         1,104          1,170             1,076                            92                            2           1,010             92    2     7   0.9817/0.000
  Gue´nard et al.   2010   Canada    Blood           French Canadian   96             89                87                               1                             1           95                1     0     8   0.0000/38.8
  Leyton et al.     2015   Chile     Blood           \-                436            809               786                              23                            0           413               22    1     7   0.6817/0.17
  rs45478192                                                                                                                                                                                                         
  Loizidou et al.   2009   Cyprus    Blood           Caucasian         1,109          1,107             1,107                            0                             0           1,109             0     0     7   Monomorphic
  Gue´nard et al.   2010   Canada    Blood           French Canadian   96             84                84                               0                             0           95                1     0     8   \-
  rs16940342                                                                                                                                                                                                         
  Chen et al.       2008   China     Blood           Asian             1,031          1,052             620                              377                           55          561               423   47    7   0.8135/0.05
  Cao et al.        2009   China     Blood           Asian             660            756               473                              252                           31          400               233   27    7   0.7228/0.12
  Jiang et al.      2016   China     Blood           Asian             351            360               233                              109                           18          206               122   23    7   0.2653/1.24
  rs249935                                                                                                                                                                                                           
  Chen et al.       2008   China     Blood           Asian             1,035          1058              762                              264                           32          720               290   25    7   0.1226/2.38
  Cao et al.        2009   China     Blood           Asian             660            756               512                              214                           30          470               176   14    7   0.2048/1.61
  Jiang et al.      2016   China     Blood           Asian             351            360               219                              129                           12          202               142   7     7   0.1801/1.80
  rs120963                                                                                                                                                                                                           
  Chen et al.       2008   China     Blood           Asian             997            1,008             488                              436                           84          428               459   110   7   0.3307/0.95
  Jiang et al.      2016   China     Blood           Asian             351            360               235                              116                           9           168               157   26    7   0.2274/1.46
  rs8053188                                                                                                                                                                                                          
  Cao et al.        2009   China     Blood           Asian             660            756               745                              11                            0           647               13    0     7   0.8403/0.04
  Gue´nard et al.   2010   Canada    Blood           French Canadian   96             92                87                               5                             0           92                4     0     8   0.7887/0.07
  rs447529                                                                                                                                                                                                           
  Cao et al.        2009   China     Blood           Asian             660            756               519                              209                           28          471               177   12    7   0.2293/1.44
  Jiang et al.      2016   China     Blood           Asian             351            360               213                              133                           14          204               139   8     7   0.2245/1.47
  rs152451                                                                                                                                                                                                           
  Gue´nard et al.   2010   Canada    Blood           French Canadian   96             94                86                               7                             1           80                14    2     8   0.0758/3.15
  Leyton et al.     2015   Chile     Blood           \-                436            809               674                              127                           8           351               79    6     7   0.4633/0.54

Meta-analysis {#sec2-6}
-------------

Statistical analyses showed that the rs120963 was associated with breast cancer risk in allelic (OR (95% CI) = 1.33 (1.18-1.49)), homozygous (OR (95% CI) = 1.74 (1.31-2.32)), dominant (OR (95% CI) = 1.42 (1.22, 1.65)) and recessive (OR (95% CI) = 1.54 (1.17, 2.03)) models. The rs249954 and rs16940342 were associated with breast cancer risk in allelic (OR (95% CI) = 1.13 (1.04, 1.23) and 1.12 (1.01, 1.24) respectively) and dominant (OR (95% CI) = 1.23 (1.09, 1.39) and 1.18 (1.04, 1.33) respectively) models. The rs249935 and rs447529 SNPs were associated with breast cancer in homozygous (OR (95% CI) = 0.67 (0.46, 0.97) and 0.51 (0.30, 0.89) respectively) and recessive (OR (95% CI) = 0.65 (0.45, 0.95) and 0.51 (0.30, 0.88) respectively) models. Other SNPs were not associated with breast cancer risk in any of the assessed genetic models. Figures [2](#F2 F3 F4){ref-type="fig"}-[5](#F5){ref-type="fig"} show forest plots for the assessed SNPs in the allelic, homozygous, dominant and recessive models respectively. Next, we analyzed associations between mentioned SNPs and breast cancer risk in distinct ethnic groups ([Table 2](#T2){ref-type="table"}). In Asians, significant associations were found between the rs249935 breast cancer in homozygous and recessive models, rs249954 and breast cancer in dominant and allelic models, and the rs120963 and breast cancer in all inheritance models. Finally, the rs447529 was associated with breast cancer in this ethnic group only in recessive model.

![Forest Plot of the Risk for *PALB2* Polymorphisms in Allelic Model. The error bars indicate 95% CIs. Solid squares represent each study in the meta-analysis. Solid diamonds represent pooled OR.](APJCP-19-2897-g002){#F2}

![Forest Plot of the Risk for *PALB2* Polymorphisms in Homozygous Model. The error bars indicate 95% CIs. Solid squares represent each study in the meta-analysis. Solid diamonds represent pooled OR.](APJCP-19-2897-g003){#F3}

![Forest Plot of the Risk for *PALB2* Polymorphisms in Dominant Model. The error bars indicate 95% CIs. Solid squares represent each study in the meta-analysis. Solid diamonds represent pooled OR.](APJCP-19-2897-g004){#F4}

![Forest Plot of the Risk for *PALB2* Polymorphisms in Recessive Model. The error bars indicate 95% CIs. Solid squares represent each study in the meta-analysis. Solid diamonds represent pooled OR.](APJCP-19-2897-g005){#F5}

###### 

Meta-analyses of *PALB2* Polymorphisms and Risk of Breast Cancer in Ethnicity-based Subgroups (NA: not assessed)

  SNP ID       Category          Allelic Model          Homozygote Model   Dominant Model   Recessive Model                                                                                        
  ------------ ----------------- ---------------------- ------------------ ---------------- ---------------------- ----- ------- ---------------------- ----- ------- ---------------------- ----- -------
  rs45532440   Caucasian         1.11 \[0.86, 1.42\]    N.A                0.42             1.06 \[0.27, 4.27\]    N.A   0.93    1.12 \[0.86, 1.45\]    N.A   0.41    1.05 \[0.26, 4.22\]    N.A   0.94
               French Canadian   2.02 \[0.60, 6.83\]    N.A                0.26             0.35 \[0.01, 8.67\]    N.A   0.52    2.79 \[0.72, 10.85\]   N.A   0.14    0.33 \[0.01, 8.11\]    N.A   0.49
  rs249954     Asian             1.13 \[1.03, 1.23\]    85                 0.008            1.20 \[0.99, 1.46\]    83    0.06    1.23 \[1.09, 1.40\]    81    0.001   1.07 \[0.89, 1.27\]    73    0.48
               French Canadian   1.25 \[0.75, 2.08\]    N.A                0.38             1.96 \[0.35, 11.17\]   N.A   0.45    1.27 \[0.70, 2.31\]    N.A   0.44    1.83 \[0.33, 10.23\]   N.A   0.49
  rs45551636   Caucasian         1.20 \[0.92, 1.55\]    71                 0.17             1.77 \[0.36, 8.73\]    0     0.49    1.19 \[0.92, 1.56\]    66    0.19    1.75 \[0.35, 8.65\]    0     0.49
               French Canadian   0.31 \[0.03, 2.96\]    N.A                0.31             0.31 \[0.01, 7.60\]    N.A   0.47    0.46 \[0.04, 5.14\]    N.A   0.53    0.31 \[0.01, 7.60\]    N.A   0.47
  rs45478192   French Canadian   2.64 \[0.11, 65.23\]   N.A                0.55             \-                     \-    \-      2.65 \[0.11, 66.04\]   N.A   0.55    \-                     \-    \-
  rs16940342   Asian             1.12 \[1.01, 1.24\]    0                  0.04             1.06 \[0.79, 1.41\]    0     0.71    1.18 \[1.04, 1.33\]    0     0.01    0.98 \[0.74, 1.31\]    0     0.91
  rs249935     Asian             0.98 \[0.88, 1.10\]    54                 0.74             0.67 \[0.46, 0.97\]    0     0.03    1.03 \[0.90, 1.17\]    52    0.67    0.65 \[0.45, 0.95\]    0     0.03
  rs120963     Asian             1.33 \[1.18, 1.49\]    89                 0.000            1.74 \[1.31, 2.32\]    81    0.000   1.42 \[1.22, 1.65\]    87    0.000   1.54 \[1.17, 2.03\]    74    0.002
  rs8053188    Asian             1.36 \[0.61, 3.04\]    N.A                0.46             \-                     \-    \-      1.36 \[0.61, 3.06\]    N.A   0.46    \-                     \-    \-
               French Canadian   0.76 \[0.20, 2.88\]    N.A                0.69             \-                     \-    \-      0.76 \[0.20, 2.91\]    N.A   0.68    \-                     \-    \-
  rs447529     Asian             0.90 \[0.77, 1.05\]    0                  0.17             0.78 \[0.48, 1.26\]    78    0.31    0.94 \[0.78, 1.12\]    0     0.48    0.51 \[0.30, 0.88\]    0     0.02
  rs152451     Caucasian         1.20 \[0.91, 1.59\]    N.A                0.19             1.44 \[0.50, 4.18\]    N.A   0.50    1.21 \[0.90, 1.63\]    N.A   0.22    1.40 \[0.48, 4.05\]    N.A   0.54
               French Canadian   2.17 \[0.95, 4.96\]    N.A                0.07             2.15 \[0.19, 24.17\]   N.A   0.54    2.15 \[0.87, 5.30\]    N.A   0.10    1.98 \[0.18, 22.20\]   N.A   0.58

Assessment of publication bias {#sec2-7}
------------------------------

The funnel plots were illustrated to evaluate the existence of publication bias in the meta-analysis of the mentioned SNPs in allelic, homozygous, dominant and recessive models (Supplementary [Figure 1A](#F1){ref-type="fig"}-[D](#F1){ref-type="fig"} respectively). The shape of the funnel plot was symmetrical implying lack of publication bias.

Discussion {#sec1-4}
==========

*PALB2* encodes a protein with fundamental role in HR and maintenance of genome stability (Leyton et al., 2015). Biallelic *PALB2* mutations are associated with increased susceptibility to cancers along with hypersensitivity to DNA-damaging materials (Reid et al., 2007). Based on the functional interaction between *PALB2* and the breast cancer susceptibility gene *BRCA2*, *PALB2* SNPs have been considered as putative risk factors for breast cancer development. In the present meta-analysis, we assessed the associations between 10 SNPs within this gene and risk of breast cancer. We found that the rs120963 was associated with breast cancer risk in all assessed genetic models. This SNP resides approximately 16.5 kb from the 3'-end of *PALB2* and was associated with breast cancer risk in Chinese population as revealed by independent studies (Chen et al., 2008; Jiang et al., 2016). Moreover, the rs249954 and rs16940342 were associated with breast cancer risk in allelic and dominant models. The rs249935 and rs447529 SNPs were associated with breast cancer in homozygous and recessive models. Other SNPs were not associated with breast cancer risk in any of the assessed genetic models. The rs152451 and rs45551636 are located in exons 4 and 9 of this gene respectively and have been previously identified through sequence analysis of the complete coding region of *PALB2* in 100 probands from South-American breast cancer families negative for BRCA1 and *BRCA2* point mutations (Leyton et al., 2015). However, our meta-analysis revealed no association between these variants and breast cancer risk. For the rs45532440, rs45478192 and rs8053188 the results of the meta-analysis were in line with the results of individual studies regarding lack of association with breast cancer risk.

In brief, our study provides further evidences for participation of *PALB2* in breast cancer risk and warrants future studies to explore the biological functions of these variants. As certain genetic variations in *PALB2* alter its functional interactions with *BRCA2* in DNA repair mechanisms and cell cycle control (Teo et al., 2013), it is possible that functional polymorphisms within this gene also affect such interactions.

Based on the detected association between five SNPs and breast cancer, we suggest the possibility of combined effects of certain SNPs in conferring breast cancer risk which should be assessed through haplotype analysis in future studies.

Our study has some limitations. First, due to the relative small number of eligible studies which assessed association of each *PALB2* SNP with breast cancer risk, we could not perform subgroup analysis. Subgroup analysis in patients with/ without family history of breast cancer, early/ late onset of breast cancer, distinct tumor subgroups or menopausal status in addition to the ethnic based analysis would explore definite role of *PALB2* in distinct types of breast cancer. As revealed recently, the association of certain SNPs with breast cancer risk may be altered by the tumor pathological features or menopausal status (Jiang et al., 2016). Second, we did not assess linkage disequilibrium (LD) between these common variants. The detected associations between these SNPs and breast cancer risk might be due to high level of LD with another causal variant which should be evaluated in future studies. Consequently, evaluation of associations between *PALB2* SNPs and breast cancer risk in large sample sizes with focus on haplotypes would clarify the complicated mechanism of maintenance of genome integrity by BRCA1 and *BRCA2* proteins in the context of breast cancer.

In conclusion, the current meta-analysis shows the associations between five SNPs of *PALB2* and breast cancer risk and confirms the results of previous studies regarding the role of this gene in the pathogenesis of breast cancer.
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